Meda's Dymista approved in UK, ready for hay fever season
This article was originally published in Scrip
Executive Summary
The UK's regulatory agency has granted marketing authorization for Meda's Dymista, a nasal formulation of fluticasone propionate and azelastine hydrochloride, for the treatment of moderate to severe seasonal and perennial allergic rhinitis.